Cargando…
ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial
INTRODUCTION: Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in combination with steroids as remission induction therapy for patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Several studies have shown that the effect on achieving (clinical)...
Autores principales: | Dirikgil, Ebru, van Leeuwen, Jolijn R, van Dam, Laura S, Bredewold, Obbo W, Ray, Argho, Jonker, Jacqueline T, Soonawala, Darius, Remmelts, Hilde H F, van Dam, Bastiaan, Bos, Willem Jan, van Kooten, Cees, Rotmans, Joris, Rabelink, Ton, Teng, Y K Onno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494556/ https://www.ncbi.nlm.nih.gov/pubmed/36130755 http://dx.doi.org/10.1136/bmjopen-2022-061339 |
Ejemplares similares
-
PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020) -
Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: van Leeuwen, Jolijn R., et al.
Publicado: (2021) -
Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results
por: Kraaij, Tineke, et al.
Publicado: (2020) -
American Pharmaceutical Associat’n
Publicado: (1869) -
A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol
por: van Rhijn-Brouwer, Femke C C, et al.
Publicado: (2018)